Plenary

Genomic Analyses of Primary Immunodeficiencies Yield Precision Medicine Treatments

Friday, June 16
10:30 AM - 11:00 AM

Massively parallel genomic DNA sequencing along with other high-powered molecular technologies have been among the great advances of the 21st century - decreasing in cost by 7 orders of magnitude and opening up new fields of investigation throughout research and clinical medicine. Genomics coupled with biochemical investigation has allowed the molecular definition of a growing number of new genetic diseases that reveal new concepts of immune regulation. Also, defining the genetic pathogenesis of these diseases has led to improved diagnosis, prognosis, genetic counseling, and, most importantly, new therapies. We highlight the investigational journey from patient phenotype to treatment using the newly defined diseases of the immune system including XMEN, PASLI, CHAI/LATAIE, and CHAPLE disease that show journeys from unknown immunological diseases to new precision medicine treatments using genomics.

Learning Objectives:

Michael Lenardo

Senior Investigator
NIH

Michael Joseph Lenardo, M.D.
Michael Lenardo was born in Chicago, Illinois on December 1, 1955. He attended the Johns Hopkins University and graduated with a Bachelor of Arts in Natural Sciences in 1977. He attended Washington University St. Louis, Mo. and obtained his Doctor of Medicine (M.D.) in 1981. He carried out clinical and research training at the University of Iowa from 1981-1985. He was then a Research Fellow at the Whitehead Institute for Biomedical Research at Massachusetts Institute of Technology with an adjunct appointment at Harvard Medical School. During this time, he carried out molecular biology research under the mentorship of Nobel laureates David Baltimore and Philip Sharp. He was then appointed Section Chief in the National Institute of Allergy and Infectious Diseases, National Institutes of Health from 1989 to the present, directing research on T-lymphocyte regulation, HIV-1, and genetic diseases of the immune system. Dr. Lenardo has published over 200 scholarly works and holds a number of medical patents. He discovered the propriocidal mechanism of immune regulation and his work has defined several genetic diseases of the immune system including the Autoimmune Lymphoproliferative Syndrome, Caspase-8 deficiency syndrome, and X-linked magnesium deficiency with EBV and neoplasia (XMEN) disease. He is currently the Director of the Clinical Genomics Program and Chief of the Molecular Development Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health. He is a Fellow of the American Association for the Advancement of Science and the American Academy of Arts and Sciences.

Presentation(s):

Send Email for Michael Lenardo


Assets

Genomic Analyses of Primary Immunodeficiencies Yield Precision Medicine Treatments



Attendees who have favorited this

Send Email for Genomic Analyses of Primary Immunodeficiencies Yield Precision Medicine Treatments